更新于：2024-11-01

calcium channel x CACNA2D1 x μ opioid receptor

更新于：2024-11-01

基本信息

关联

项与 calcium channel x CACNA2D1 x μ opioid receptor 相关的药物

TLI-0326

靶点

CACNA2D1 x calcium channel x μ opioid receptor

作用机制

CACNA2D1调节剂 [+2]

在研机构-

原研机构

Trinity Laboratories, Inc.

在研适应症-

非在研适应症

糖尿病性神经病变 [+2]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

Pregabalin/tramadol (Laboratorios Silanes)

靶点

CACNA2D1 x μ opioid receptor

作用机制

CACNA2D1调节剂 [+1]

在研机构-

原研机构

Laboratorios Silanes SA de CV

在研适应症-

非在研适应症

神经痛

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与 calcium channel x CACNA2D1 x μ opioid receptor 相关的临床试验

NCT05324059 / Completed临床3期

Confirmatory Study of Efficacy and Safety of the Pregabalin/Tramadol Combination Versus Pregabalin in the Management of Acute Pain of Neuropathic Origin.

Phase IIIb confirmatory study of efficacy and safety, longitudinal, multicenter, randomized, double-blind study of the combination Pregabalin/Tramadol versus Pregabalin in the management of acute pain of neuropathic origin.

开始日期2022-07-11

申办/合作机构

Laboratorios Silanes SA de CV

NCT05389150 / Completed临床1期

Pharmacokinetic Non-interaction Study Between Pregabalin 150 mg and Tramadol 50 mg, Administered Individually or in Combination, Single Dose in Healthy Subjects of Both Genders Under Fasting Conditions

The study was carried out in the Clinical Unit and Analytical Unit of the Department of Pharmacology and Toxicology of the Faculty of Medicine of the Universidad Autónoma de Nuevo León, with the aim of comparing the bioavailability (maximum concentration and area under the curve) of an oral formulation containing Pregabalin 150 mg/Tramadol 50 mg in combination with the two oral formulations Pregabalin 150 mg or Tramadol 50 mg administered as a single dose, in healthy subjects under fasting conditions.

开始日期2019-01-17

申办/合作机构

Laboratorios Silanes SA de CV

100 项与 calcium channel x CACNA2D1 x μ opioid receptor 相关的临床结果

登录后查看更多信息

100 项与 calcium channel x CACNA2D1 x μ opioid receptor 相关的转化医学

登录后查看更多信息

0 项与 calcium channel x CACNA2D1 x μ opioid receptor 相关的专利（医药）

登录后查看更多信息

项与 calcium channel x CACNA2D1 x μ opioid receptor 相关的文献（医药）

2018-11-01·Journal of Psychiatric Research2区 · 医学

Voltage-gated calcium channel activity and complex related genes and schizophrenia: A systematic investigation based on Han Chinese population

2区 · 医学

Article

作者: Chen, Gang ; Rice, John P ; Guan, Fanglin ; Yan, Zhilan ; Zhu, Li ; Ni, Tong ; Zhang, Tianxiao ; Liu, Dan ; Lin, Huali

Schizophrenia (SCZ) is a devastating mental disorder affecting approximately 1% of the worldwide population. Early studies have indicated that genetics plays an important role in the onset and development of SCZ. Accumulating evidence supports that SCZ is linked to abnormalities of synapse transmission and synaptic plasticity. Voltage-gated calcium channel (VGCC) subunits are critical for mediating intracellular Ca^2 + influx and therefore are responsible for changing neuronal excitability and synaptic plasticity. To systematically investigate the role of calcium signaling genes in SCZ susceptibility, we conducted a case-control study that included 2518 SCZ patients and 7521 healthy controls with Chinese Han ancestry. Thirty-seven VGCC genes, including 363 tag single nucleotide polymorphisms (SNPs), were examined. Our study replicated the following previously identified susceptible loci: CACNA1C, CACNB2, OPRM1, GRM7 and PDE4B. In addition, several novel loci including CACNA2D1, PDE4D, NALCN, and CACNA2D3 were also identified to be associated with SCZ in our Han Chinese sample. Combined with GTEx eQTL data, we have shown that CASQ2, ITGAV, and TMC2 can be also added into the prioritization list of SCZ susceptible genes. Two-way interaction analyses identified widespread gene-by-gene interactions among VGCC activity and complex-related genes for the susceptibility of SCZ. Further sequencing based studies are still needed to unravel potential contributions of schizophrenia risk from rare or low frequency variants of these candidate genes.